[Combination (RaHPP) of radiotherapy, hyperthermia and chemotherapy (peplomycin and picibanil) for bladder cancer]. 1984

H Washida, and M Tsugaya, and N Hirao, and Y Hachisuka

Four patients with urinary bladder carcinoma were treated by combination therapy which consisted of hyperthermia vesical irrigation of two anticancer drugs (peplomycin and picibanil), intravesical instillation of those drugs and radiation. Following the therapeutic method we planned, 40 mg of peplomycin and 10 KE of picibanil in 1,500 ml of sterile distilled water was irrigated at 42 to 43 degrees C into the bladder for 3 hours; 40 mg of peplomycin and 10 KE of picibanil in 40 ml of sterile distilled water was instilled into the bladder; and, the focus was irradiated with 60Co to a focal dose of 200 rad 30 minutes later. This pattern of treatment was repeated once a week, 3 to 5 times in total. On the days this pattern was not taken, 5 KE of picibanil in 20 ml of sterile distilled water was instilled into the bladder cavity. Complete response was observed in one patient and partial response in 3 patients. The side effect was temporary irritable bladder symptom.

UI MeSH Term Description Entries
D006979 Hyperthermia, Induced Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs. Fever Therapy,Hyperthermia, Local,Hyperthermia, Therapeutic,Thermotherapy,Induced Hyperthermia,Therapeutic Hyperthermia,Therapy, Fever,Local Hyperthermia
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010844 Picibanil A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity. NSC-B116209,OK-432,Picibanyl,Streptococcal OK-432,Streptococcal Preparation OK-432,NSC B116209,NSCB116209,OK 432,OK432,Streptococcal OK 432,Streptococcal OK432,Streptococcal Preparation OK 432,Streptococcal Preparation OK432
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females

Related Publications

H Washida, and M Tsugaya, and N Hirao, and Y Hachisuka
November 2010, Oncology (Williston Park, N.Y.),
H Washida, and M Tsugaya, and N Hirao, and Y Hachisuka
July 1979, Urology,
H Washida, and M Tsugaya, and N Hirao, and Y Hachisuka
December 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
H Washida, and M Tsugaya, and N Hirao, and Y Hachisuka
June 2016, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group,
H Washida, and M Tsugaya, and N Hirao, and Y Hachisuka
September 1988, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
H Washida, and M Tsugaya, and N Hirao, and Y Hachisuka
December 1993, Hinyokika kiyo. Acta urologica Japonica,
H Washida, and M Tsugaya, and N Hirao, and Y Hachisuka
February 1999, Hinyokika kiyo. Acta urologica Japonica,
H Washida, and M Tsugaya, and N Hirao, and Y Hachisuka
January 1992, Cancer chemotherapy and pharmacology,
H Washida, and M Tsugaya, and N Hirao, and Y Hachisuka
January 1998, Cancer surveys,
H Washida, and M Tsugaya, and N Hirao, and Y Hachisuka
August 2003, Critical reviews in oncology/hematology,
Copied contents to your clipboard!